1. Investment Snapshot
2. Thesis
3. Valuation & Price Target
4. Business & Product Moat
5. People & Governance
6. Market & Macro
7. Financial Quality
8. Risk Register
9. Prediction Market
10. 𝕏 Posts
Discussion
1. Investment Snapshot
2. Thesis
3. Valuation & Price Target
4. Business & Product Moat
5. People & Governance
6. Market & Macro
7. Financial Quality
8. Risk Register
9. Prediction Market
10. 𝕏 Posts
Discussion
1. Investment Snapshot
2. Metrics vs Peers
3. Price Chart
4. Valuation
5. Offer Terms
6. Financial Statements
Discussion
Research report, target price, DCF and forensic scores are for subscribers. View plans
Symbol
PPCB
Listed on
2025-08-15
Sector
Health Care
Subsector
Pharmaceuticals
Offer Price
$4.00
Shares Offered
1M
12.81M
$50.4M
7.8%
Implied Upside vs Midpoint
Description
The Company was originally formed in Melbourne, Victoria, Australia on October 15, 2007 as Propanc PTY LTD. On November 23, 2010, Propanc Health Group Corporation was incorporated in the State of Delaware and in January 2011, to reorganize our Company, whereby Propanc PTY LTD became our wholly-owned subsidiary. Effective April 20, 2017, we changed our name to “Propanc Biopharma, Inc.” to better reflect our current stage of operations and development. We are a development-stage healthcare company that is currently focused on developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancer. Utilizing our scientific and oncology consultants, we have developed a rational, composite formulation of anti-cancer compounds, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Our lead product candidate, PRP, is a variation upon our novel formulation and involves pro-enzymes, the inactive precursors of enzymes. --- Our principal executive offices are located at 302, 6 Butler Street Camberwell, VIC, 3124 Australia. Our telephone number is +61-03-9882-0780. Our website: www.propanc.com.
| Metric | Value | Peer median | Among peers | |
|---|---|---|---|---|
Net cash / market cap | -1.0% | 0.7% | ||
Debt / equity | 0.04 | 0.00 | ||
Current ratio | 1.50 | 0.27 | ||
9 premium metrics: DCF value / price, Growth the price needs: how common, Last 12 months vs full year and 6 more Unlock | ||||
Each filing is plotted ahead of the first trading day on the price chart.
| Filed | Form | Price range | Price | Shares offered | Deal size |
|---|---|---|---|---|---|
| 2011-06-23 | S-1 | — | $1.50 | 19,383,174 | $29.1M |
| 2011-08-18 | S-1/A | — | $1.50 | 5,000,000 | $7.5M |
| 2011-09-30 | S-1/A | — | $1.50 | 5,000,000 | $7.5M |
| 2011-10-27 | S-1/A | — | $1.50 | 5,000,000 | $7.5M |
| 2011-11-14 | S-1/A | — | $1.50 | 5,000,000 | $7.5M |
| 2011-12-08 | S-1/A | — | $1.50 | 5,000,000 | $7.5M |
| 2011-12-16 | 424B3 | — | $1.50 | 5,000,000 | $7.5M |
| 2015-11-23 | S-1 | — | $0.60 | 98,404,985 | $59.0M |
| 2016-03-25 | S-1 | — | $0.60 | 171,000,000 | $102.6M |
| 2016-07-06 | 424B3 | — | $0.01 | 98,404,985 | $1.0M |
| 2016-07-06 | 424B3 | — | $0.01 | 171,000,000 | $1.7M |
| 2016-08-04 | 424B3 | — | $0.10 | 98,404,985 | $9.8M |
| 2016-08-04 | 424B3 | — | $0.10 | 171,000,000 | $17.1M |
| 2016-08-19 | S-1 | — | $0.10 | 240,000,000 | $24.0M |
| 2016-08-26 | 424B3 | — | — | 98,404,985 | — |
| 2016-08-26 | 424B3 | — | — | 171,000,000 | — |
| 2016-09-19 | 424B3 | — | — | 98,404,985 | — |
| 2016-09-19 | 424B3 | — | — | 171,000,000 | — |
| 2016-11-18 | 424B3 | — | — | 98,404,985 | — |
| 2016-11-18 | 424B3 | — | — | 171,000,000 | — |
| 2016-12-12 | 424B3 | — | — | 171,000,000 | — |
| 2016-12-12 | 424B3 | — | — | 98,404,985 | — |
| 2017-01-06 | 424B3 | — | — | 171,000,000 | — |
| 2017-01-06 | 424B3 | — | — | 98,404,985 | — |
| 2017-02-07 | 424B3 | — | — | 171,000,000 | — |
| 2017-02-07 | 424B3 | — | — | 98,404,985 | — |
| 2017-04-26 | 424B3 | — | — | 171,000,000 | — |
| 2018-10-17 | S-1 | — | $0.07 | 60,454,321 | $4.2M |
| 2018-10-30 | 424B3 | — | $0.07 | 60,454,321 | $4.2M |
| 2019-02-25 | S-1 | — | — | 111,203,954 | — |
| 2019-03-07 | 424B3 | — | — | 111,203,954 | — |
| 2019-05-23 | S-1 | — | $0.01 | — | — |
| 2019-06-14 | S-1/A | — | $0.01 | 1,428,571 | $0.0M |
| 2019-12-12 | S-1 | — | $0.30 | 3,055,556 | $0.9M |
| 2020-05-13 | S-1 | — | $0.20 | 150,000,000 | $30.0M |
| 2020-06-26 | S-1/A | — | $0.20 | 150,000,000 | $30.0M |
| 2020-07-17 | S-1/A | — | $0.20 | 150,000,000 | $30.0M |
| 2020-08-13 | S-1/A | — | $0.20 | 150,000,000 | $30.0M |
| 2020-10-14 | S-1/A | — | $0.20 | 150,000,000 | $30.0M |
| 2020-11-03 | S-1/A | — | $0.20 | 150,000,000 | $30.0M |
| 2022-02-22 | 424B3 | — | — | 40,000,000 | — |
| 2023-04-04 | 424B3 | — | $40.00 | 23,750 | $0.9M |
| 2023-10-17 | 424B4 | — | $0.01 | 26,250,000 | $0.3M |
| 2025-08-18 | 424B3 | — | — | 3,091,500 | — |
| 2025-08-18 | 424B4 | — | $4.00 | 1,000,000 | $4.0M |
Propanc Biopharma, Inc. income statement and balance sheet, FY Jun 2023 to FY Jun 2026, as reported in SEC filings.
| Metric | FY Jun 2023 | FY Jun 2024 | FY Jun 2025 | FY Jun 2026after listing |
|---|---|---|---|---|
| Operating income | ($1.8M) | ($1.5M) | ($57.3M) | ($18.2M) |
| Net income | ($2.7M) | ($1.8M) | ($58.9M) | ($18.9M) |
| Metric | FY Jun 2023 | FY Jun 2024 | FY Jun 2025 | FY Jun 2026after listing |
|---|---|---|---|---|
| Total assets | $60.3K | $72.4K | $19.6M | $12.8M |
| Total liabilities | $3.2M | $3.9M | $5.7M | $3.4M |
| Total equity | ($3.1M) | ($3.8M) | $13.9M | $9.4M |
| Cash & equivalents | $10.0K | $21.1K | $12.1K | $832K |